指南与共识肾移植水电解质与酸碱

CARI指南:平衡电解质溶液改善肾移植结局的循证推荐

CARI Guideline: Evidence-Based Recommendations for Balanced Electrolyte Solutions to Improve Kidney Transplant Outcomes.
指南 / 共识 · Kidney Int Rep · 2025-06-06

该指南由澳大利亚和新西兰多学科工作组制定,基于随机对照试验的系统综述与Meta分析及BEST Fluids试验数据,采用GRADE方法评估证据。推荐 deceased donor 肾移植使用平衡电解质溶液(中等确定性证据),活体供肾移植仅建议使用(低确定性证据),并指出需进一步研究患者中心结局和儿童人群。

要点

  • deceased donor 肾移植推荐使用平衡电解质溶液(中等确定性证据)。
  • 活体供肾移植仅建议使用平衡电解质溶液(低确定性证据)。
  • 平衡电解质溶液与生理盐水相比,移植物功能延迟风险降低18%(RR 0.82,95%CI 0.71-0.94)。

核心结论

  • deceased donor 肾移植推荐使用平衡电解质溶液(中等确定性证据),活体供肾移植仅建议使用(低确定性证据)。
  • 需进一步研究患者中心结局和儿童人群使用平衡溶液以优化肾移植照护。

研究设计与样本

  • 指南由澳大利亚和新西兰多学科工作组制定,包括有肾移植亲身经历的消费者。
  • 基于近期发表的随机对照试验系统综述与Meta分析(包括BEST Fluids试验数据),评估平衡电解质溶液对比生理盐水在肾移植中的效果。
  • 绝对效应基于国家注册中心或纳入试验对照组事件率的SONG移植核心结局基线风险确定,所有结局采用GRADE证据确定性评估。
  • 采用GRADE证据到决策框架制定照护推荐和临床实践要点。

主要发现

  • 平衡电解质溶液对比生理盐水使移植物功能延迟减少18%(7项研究,1306名参与者,风险比0.82;95%置信区间0.71-0.94),活体与 deceased donor 间无差异。
  • deceased donor 中,平衡电解质溶液对比生理盐水使移植物功能延迟有临床重要减少(每1000名患者减少69例;95%置信区间减少111至23例)。
  • deceased donor 中,平衡电解质溶液对比生理盐水对高钾血症影响不明确但可能无差异(每1000名患者减少66例;95%置信区间减少207至增加136例)。
  • 活体供肾中,平衡电解质溶液对移植物功能延迟风险获益非常小(每1000名患者减少7例;95%置信区间减少12至2例)。
  • 活体供肾中,平衡电解质溶液对比生理盐水对高钾血症影响不明确但可能无差异(每1000名患者减少25例;95%置信区间减少79至增加52例)。

关键数值与推荐

  • deceased donor 肾移植推荐使用平衡电解质溶液(中等确定性证据)。
  • 活体供肾移植建议使用平衡电解质溶液(低确定性证据)。
  • 平衡电解质溶液对比生理盐水:移植物功能延迟风险比0.82(95%置信区间0.71-0.94)。
  • deceased donor 移植物功能延迟绝对效应:每1000名患者减少69例(95%置信区间减少111至23例)。
  • deceased donor 高钾血症绝对效应:每1000名患者减少66例(95%置信区间减少207至增加136例)。

临床怎么用

  • deceased donor 肾移植中推荐使用平衡电解质溶液而非生理盐水(中等确定性证据)。
  • 活体供肾移植中建议使用平衡电解质溶液(低确定性证据)。

局限性

  • 需进一步研究患者中心结局和儿童人群使用平衡溶液以优化肾移植照护。
  • 平衡电解质溶液对比生理盐水对高钾血症的影响不明确( deceased donor:每1000名患者减少66例,95%置信区间减少207至增加136例;活体供肾:每1000名患者减少25例,95%置信区间减少79至增加52例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Kidney transplantation is an optimal treatment for kidney failure; however, delayed graft function is a common complication with a prevalence of up to 40% in deceased donor transplantation. The use of i.v. fluids during kidney transplantation is required for hemodynamic stability; however, there are concerns that normal saline may contribute to increased delayed graft function and hyperchloremic metabolic acidosis. Balanced electrolyte solutions have been suggested as an alternative i.v. fluid that may decrease delayed graft function. However, there have been concerns that this may increase hyperkalemia in transplant recipients. This guideline seeks to synthesize the available evidence and make recommendations for the Australian and New Zealand care by a multidisciplinary working group, including consumers with lived experience of kidney transplantation. A recently published systematic review and meta-analysis of randomized controlled trials (RCTs), including data from the BEST Fluids trial, evaluating balanced electrolyte solutions versus normal saline in kidney transplants was identified and absolute effects were determined using baseline risks of SONG Transplant Core outcomes from either national registries or event rates in the control arms of the included trials. All outcomes were assessed using the GRADE certainty of evidence. The GRADE Evidence-to-Decision framework was used to develop recommendations for care and clinical practice points. Balanced electrolyte solution compared with normal saline resulted in an 18% reduction in delayed graft function (7 studies, 1306 participants, risk ratio: 0.82; 95% confidence interval [CI]: 0.71-0.94) and no differences across living and deceased donation were evident. In deceased donation, balanced electrolyte solution compared with normal saline has a clinically important decrease in delayed graft function (69 fewer per 1000 patients; 95% CI: 111 to 23 fewer]). The use of balanced electrolyte solution compared with normal saline has an unclear effect on hyperkalemia but it may be no different (66 fewer per 1000 patients; 95% CI: 207 fewer to 136 more). In living donation, the use of balanced electrolyte solutions had very small benefits on the risk of delayed graft function (7 few per 1000 patients; 95% CI: 12 fewer to 2 fewer). In those receiving a living donor kidney transplant, the effects of balanced electrolyte solutions compared with normal saline on hyperkalemia were unclear but are likely to be no different (25 fewer per 1000 patients; 95% CI: 79 fewer to 52 more). Balanced electrolyte solutions are recommended for deceased donor transplants, with a moderate certainty of evidence. However, in living donation transplants balanced electrolyte solutions are only suggested with a low degree of certainty of evidence. Further research is needed on patient-centered outcomes and the use of balanced solutions in pediatric populations to optimize kidney transplant care.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. O'Reilly C, Tunnicliffe D, Blackley A, et al. CARI Guideline: Evidence-Based Recommendations for Balanced Electrolyte Solutions to Improve Kidney Transplant Outcomes. Kidney Int Rep. 2025. PMID: 40814637. doi:10.1016/j.ekir.2025.05.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。